GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Forward PE Ratio

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Forward PE Ratio : 0.00 (As of Jun. 02, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Forward PE Ratio?

Arcturus Therapeutics Holdings's Forward PE Ratio for today is 0.00.

Arcturus Therapeutics Holdings's PE Ratio without NRI for today is 0.00.

Arcturus Therapeutics Holdings's PE Ratio for today is 0.00.


Arcturus Therapeutics Holdings Forward PE Ratio Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Forward PE Ratio Chart

Arcturus Therapeutics Holdings Annual Data
Trend 2021-12 2022-12 2023-03
Forward PE Ratio
4.75 2.47 2.24

Arcturus Therapeutics Holdings Quarterly Data
2021-09 2021-12 2022-12 2023-03
Forward PE Ratio 1.89 4.75 2.47 2.24

Competitive Comparison of Arcturus Therapeutics Holdings's Forward PE Ratio

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Forward PE Ratio falls into.



Arcturus Therapeutics Holdings Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Arcturus Therapeutics Holdings  (NAS:ARCT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Arcturus Therapeutics Holdings Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines

From GuruFocus

Arcturus Therapeutics to Attend the Following Investor Conferences

By Business Wire Business Wire 09-01-2022

Arcturus Therapeutics to Attend Upcoming Investor Conferences

By Business Wire Business Wire 02-06-2023